Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
AAU / Almaden Minerals Ltd. FORM 6-K (Current Report of Foreign Issuer)

2018-07-16 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EX
AAU

0
Almaden Achieves 39% Gold And 47% Silver Mill Feed Grade Increase From Bulk Ore Sort Tests for Ixtaca

2018-07-16 globenewswire
VANCOUVER, British Columbia, July 16, 2018 (GLOBE NEWSWIRE) -- Almaden Minerals Ltd. (“Almaden” or “the Company”) (TSX:AMM) (NYSE American:AAU) is pleased to announce that it has achieved positive results from ore sorting trials carried out on ore samples from the Ixtaca gold-silver project located in Puebla State, Mexico. The ore sorting tests were carried out on a commercial XRT sorter using a bulk sample from the limestone host rock in the Ixtaca Main zone.
AMZ AAU AMM AXDDF

2
AAU / Almaden Minerals Ltd. FORM 6-K (Current Report of Foreign Issuer)

2018-06-29 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EX
AAU

2
AAU / Almaden Minerals Ltd. FORM 6-K (Current Report of Foreign Issuer)

2018-06-29 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K &nb
AAU

5
Almaden Announces Results of Annual General Meeting

2018-06-28 globenewswire
VANCOUVER, British Columbia, June 28, 2018 (GLOBE NEWSWIRE) -- Almaden Minerals Ltd. (“Almaden" or the "Company") (TSX:AMM) (NYSE American:AAU) is pleased to provide the results of its Annual General Meeting held on June 28, 2018.
AMZ AAU AMM AXDDF

6
AAU / Almaden Minerals Ltd. FORM 6-K (Current Report of Foreign Issuer)

2018-06-15 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K &nb
AAU

2
AAU / Almaden Minerals Ltd. FORM 6-K (Current Report of Foreign Issuer)

2018-06-15 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K &nb
AAU

4
AAU / Almaden Minerals Ltd. FORM 6-K (Current Report of Foreign Issuer)

2018-06-12 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K &nb
AAU

3
AAU / Almaden Minerals Ltd. FORM 6-K (Current Report of Foreign Issuer)

2018-06-07 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EX
AAU

5
Almaden Closes Oversubscribed $9.4 Million Non-Brokered Private Placement

2018-06-07 globenewswire
VANCOUVER, British Columbia, June 07, 2018 (GLOBE NEWSWIRE) -- Almaden Minerals Ltd. (“Almaden” or “the Company”) (TSX:AMM) (NYSE American:AAU) is pleased to announce that it has closed its previously announced non-brokered private placement with the issuance of 9,440,000 units (“Units”) at $1.00 per Unit (the “Offering”). Each Unit consisted of one common share of the Company (a “Common Share”) and one-half of one non-transferable Common Share purchase warrant (each such whole Common Share purchase warrant, a “Warrant”).
AMZ AAU AMM AXDDF

3
AAU / Almaden Minerals Ltd. FORM 6-K (Current Report of Foreign Issuer)

2018-06-01 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EX
AAU

7
AAU / Almaden Minerals Ltd. FORM 6-K (Current Report of Foreign Issuer)

2018-05-18 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
AAU

10
AAU / Almaden Minerals Ltd. FORM 6-K (Current Report of Foreign Issuer)

2018-05-11 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EX
AAU

6
Almaden Announces $7 Million Non-Brokered Private Placement

2018-05-11 globenewswire
VANCOUVER, B.C., May 11, 2018 (GLOBE NEWSWIRE) -- Almaden Minerals Ltd. (“Almaden” or “the Company”) (TSX:AMM) (NYSE American:AAU) is pleased to announce a proposed non-brokered private placement financing (the "Offering") of up to 7,000,000 units (the “Units”) to raise up to $7,000,000 at a price of $1.00 per Unit.
AMZ AAU AMM AXDDF

2
AAU / Almaden Minerals Ltd. FORM 6-K (Current Report of Foreign Issuer)

2018-05-10 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
AAU

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to AAU / Almaden Minerals Ltd. on message board site Silicon Investor.

Armada Gold 10 Million oz of Gold u0026 1 billion lb of Cu ! ARMADA GOLD(AAU) or ADRIAN RESOURCES?
Armada Gold Corporation AAU-Calgary
CUSIP: 020283107